Cephalon Inc. et al v. Watson Laboratories Inc.
Filing 144
MEMORANDUM AND ORDER re (123 in 1:10-cv-00007-GMS, 114 in 1:10-cv-00055-GMS, 51 in 1:11-cv-00782-GMS, 136 in 1:10-cv-00695-GMS, 115 in 1:10-cv-00210-GMS, 180 in 1:10-cv-01078-GMS, 300 in 1:10-md-02200-GMS) MOTION for Judgment as a Matter of Law < i>(Plaintiffs' Rule 52(c)) filed by Cephalon, Inc., Cephalon France, Cephalon Inc., (122 in 1:10-cv-00055-GMS, 59 in 1:11-cv-00782-GMS, 145 in 1:10-cv-00695-GMS, 123 in 1:10-cv-00210-GMS, 189 in 1:10-cv-01078-GMS, 314 in 1:10-md-02200- GMS, 131 in 1:10-cv-00007-GMS) POST Trial Brief filed by Cephalon, Inc., Cephalon France, Cephalon Inc., (319 in 1:10-md-02200-GMS, 128 in 1:10-cv-00210-GMS) Proposed Findings of Fact filed by Armodafinil Patent Litigation, Lupin Pharmaceuticals Inc., Lupin Limited. Signed by Chief Judge Gregory M. Sleet on 3/30/2013. Associated Cases: 1:10-md-02200-GMS et al.(asw)
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
